The phytoestrogen ferutinin affects female sexual behavior modulating ERalpha expression in the hypothalamus.
This study was designed to assess the effect of the phytoestrogenic compound ferutinin, chronically administered in ovariectomized progesterone primed rats, alone or in combination with estradiol benzoate. After 2, 3 and 4 weeks of treatments, female rats were tested for receptive (lordosis) and proceptive behaviors (hops, darts and ear wigglings). Ferutinin given alone markedly increased the intensity of the lordotic response in ovariectomized rats but failed to significantly affect proceptivity. On the other hand estradiol benzoate significantly increased both receptive and proceptive behaviors. When administered in combination with estradiol, ferutinin reduced the increase in receptivity and proceptivity due to estrogen effects, acting as an antiestrogen. At the end of the behavioral experiments, animals were sacrificed and Western blot analysis of estrogen receptor alpha (ERalpha) levels was performed in the dissected hypothalami. Ferutinin increased ERalpha expression when administered alone, as estradiol did, but decreased the response to estradiol when administered in combination. These results suggest that ferutinin displays estrogenic or antiestrogenic activity through ERalpha in the hypothalamus, depending on the absence or the presence of estrogen priming.
Zanoli
Paola
P
Department of Biomedical Sciences, Section of Pharmacology, and National InterUniversity Consortium for the Study of Natural Active Principles (CINSPAN), University of Modena and Reggio Emilia, Via Campi 287, 41100 Modena, Italy. zanoli.paola@unimore.it
Zavatti
Manuela
M
Geminiani
Elisa
E
Corsi
Lorenzo
L
Baraldi
Mario
M
D000818:Animals; D001565:Benzoates / Q000008:administration & dosage / Q000494:pharmacology*; D001643:Bridged Bicyclo Compounds / Q000008:administration & dosage / Q000494:pharmacology; D003508:Cycloheptanes / Q000008:administration & dosage / Q000494:pharmacology*; D004958:Estradiol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D047628:Estrogen Receptor alpha / Q000037:antagonists & inhibitors* / Q000096:biosynthesis*; D005260:Female; D007031:Hypothalamus / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D010052:Ovariectomy; D048789:Phytoestrogens / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012717:Sesquiterpenes / Q000008:administration & dosage / Q000494:pharmacology*; D012726:Sexual Behavior, Animal / Q000187:drug effects*
D001565:Benzoates; D001643:Bridged Bicyclo Compounds; D003508:Cycloheptanes; D047628:Estrogen Receptor alpha; D048789:Phytoestrogens; D012717:Sesquiterpenes; C074283:estradiol 3-benzoate; C111068:4-oxy-6-(4-oxybezoyloxy)dauc-8,9-en; D004958:Estradiol